KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Current Investments (2016 - 2025)

Exact Sciences (EXAS) has disclosed Cash & Current Investments for 16 consecutive years, with $964.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 7.06% to $964.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $964.7 million, a 7.06% decrease, with the full-year FY2025 number at $964.7 million, down 7.06% from a year prior.
  • Cash & Current Investments was $964.7 million for Q4 2025 at Exact Sciences, down from $1.0 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.4 billion in Q1 2021 to a low of $632.1 million in Q4 2022.
  • A 5-year average of $901.9 million and a median of $837.7 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: crashed 45.09% in 2022, then surged 39.04% in 2024.
  • Exact Sciences' Cash & Current Investments stood at $1.0 billion in 2021, then plummeted by 38.66% to $632.1 million in 2022, then rose by 23.03% to $777.6 million in 2023, then skyrocketed by 33.48% to $1.0 billion in 2024, then dropped by 7.06% to $964.7 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Cash & Current Investments are $964.7 million (Q4 2025), $1.0 billion (Q3 2025), and $858.4 million (Q2 2025).